{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KMT2Ar", "query": { "condition": "KMT2Ar" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KMT2Ar&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:14:13.198Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Lineage Leukemia Gene Mutation", "Refractory AML", "AML With Mutated NPM1", "Acute Myeloid Leukemia Recurrent", "Acute Myeloid Leukemia, in Relapse", "NPM1 Mutation", "KMT2Ar", "Myeloid Sarcoma", "Nucleophosmin 1-mutated Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-07-18", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 44, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735184" }, { "nct_id": "NCT06001788", "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "AML With Mutated NPM1", "Hematologic Malignancy", "KMT2Ar", "NPM1 Mutation", "MLL Rearrangement", "Leukemia", "Acute Myeloid Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Acute Leukemia", "Neoplasms by Histologic Type" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2024-02-22", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 38, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001788" }, { "nct_id": "NCT06222580", "title": "SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With KMT2A Rearrangement", "Acute Myeloid Leukemia With NPM1 Mutation", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Revumenib", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Uma Borate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-20", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 4, "location_summary": "Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06222580" }, { "nct_id": "NCT05326516", "title": "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Leukemias", "Acute Lymphoblastic Leukemia", "Acute Lymphocytic Leukemia", "Mixed Phenotype Acute Leukemia", "Acute Myeloid Leukemia", "Acute Undifferentiated Leukemia" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Chemotherapy Regimen 1", "type": "DRUG" }, { "name": "Chemotherapy Regimen 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": null, "sex": "ALL", "summary": "30 Days and older" }, "enrollment_count": 30, "start_date": "2022-03-09", "completion_date": "2024-07-29", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 10, "location_summary": "San Francisco, California • Boston, Massachusetts • Kansas City, Missouri + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05326516" }, { "nct_id": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Leukemia, Lymphocytic, Acute", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Enzomenib", "type": "DRUG" }, { "name": "azoles", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Intensive chemotherapy with 7 + 3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 606, "start_date": "2022-02-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 33, "location_summary": "Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04988555" }, { "nct_id": "NCT05886049", "title": "Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia With KMT2A Rearrangement", "Acute Myeloid Leukemia With NPM1 Mutation" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Revumenib", "type": "DRUG" }, { "name": "Transthoracic Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2024-06-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 22, "location_summary": "Orange, California • Sacramento, California • Aventura, Florida + 19 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05886049" }, { "nct_id": "NCT03724084", "title": "Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pinometostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 6, "start_date": "2019-04-10", "completion_date": "2022-11-14", "has_results": true, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Columbus, Ohio", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03724084" }, { "nct_id": "NCT04065399", "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Mixed Lineage Acute Leukemia", "Mixed Phenotype Acute Leukemia", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "revumenib", "type": "DRUG" }, { "name": "cobicistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": null, "sex": "ALL", "summary": "30 Days and older" }, "enrollment_count": 447, "start_date": "2019-11-05", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 22, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 17 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04065399" }, { "nct_id": "NCT07355335", "title": "Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KMT2A-rearranged", "NPM1-mutant Refractory or Relapsed AML" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 24, "start_date": "2026-07-09", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07355335" }, { "nct_id": "NCT02828358", "title": "Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "B Acute Lymphoblastic Leukemia", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "364 Days", "sex": "ALL", "summary": "Up to 364 Days" }, "enrollment_count": 78, "start_date": "2017-04-01", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-05-22T09:14:13.198Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02828358" } ] }